8results about How to "Improve expression level" patented technology

The application discloses a drought-inducible promoter of Cotinus coggygria and application thereof, a DNA sequence of the promoter is shown as SEQ ID No. 1, proCcDT1 is cloned from a promoter region of a CcDT1 gene of the Cotinus coggygria and is verified through experiments. First, elements of the promoter region are analyzed, and the result shows that the elements contain multiple cis-acting elements that can be involved in response to abiotic stress. Then, proCcDT1-GUS transgenic plants are treated through 10% PEG simulation drought, and it is found that GUS staining of the transgenic plants is enhanced, so it can be concluded that the GUS expression level driven by the promoter is increased under drought induction conditions, and it is also proved that the promoter can be induced by drought stress. The promoter proCcDT1 is introduced into an Arabidopsis genome through genetic transformation technology, so that the promoter can be stably induced by drought stress in a heterologous plant, and the practical application has important value for cultivating drought-resistant Cotinus coggygria varieties.

The application relates to application of miRNA and / or a miRNA agonist in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury, and belongs to the technical field of biological medicine. The medicine is administered through skeletal muscle injection, is secreted to a circulation system after expression on the skeletal muscle, is delivered to heart tissue by taking extracellular vesicles as carriers, and thus regulates myocardial cell functions. According to the animal model verification result, the miRNA can be delivered to the heart by the extracellular vesicles secreted by the skeletal muscle through injection of the medicine into the skeletal muscle, the expression level of the miRNA in the I / RI heart is significantly increased, the myocardial infarction area is effectively reduced, myocardial cell apoptosis is inhibited, myocardial fibrosis is reduced, and heart function is improved, a brand-new intervention strategy is provided for treatment of myocardial ischemia-reperfusion injury and related heart diseases, and a brand-new idea is opened up for research and development of heart failure treatment medicines.

This invention relates to a therapeutic target for metabolic dysfunction-related fatty liver disease (MAFLD) and hepatitis, and its application, belonging to the field of biomedical technology. This invention is the first to discover that the expression level of DPF2 in Lgr5-positive hepatocytes can specifically determine the severity of MAFLD and MASH. Based on this finding, this invention significantly improves the pathological structure of MASH by overexpressing DPF2 in Lgr5-positive hepatocytes, demonstrating that targeting Lgr5-positive hepatocytes in the liver can be a therapeutic strategy for metabolic-related fatty liver disease. This invention provides a novel therapeutic target for the treatment of MAFLD / MASH, which has good specificity and broad application prospects.

The application belongs to the technical field of bioengineering, and discloses a screening platform for optimizing the interval of baculovirus bidirectional promoters, a screening method and application. The application constructs a high-resolution screening platform with a reference gene integrated in a virus skeleton, and through two-stage screening, first, a transcription enhancement interval is determined by rough screening in the 98-245bp interval, and then, fine screening is performed in the transcription enhancement interval by 1bp steps, so that the optimal interval length of the p10 and polh promoters is determined as 153bp by normalizing the reference fluorescent signal to correct errors such as infection efficiency. The interval is applied to a recombinant adeno-associated virus (rAAV) packaging system, transcription interference between the bidirectional promoters is eliminated, the expression balance of Rep and Cap proteins is restored, the rAAV genome replication efficiency is improved by 3 times, the empty shell rate is reduced from 84.9% to 20.1%, and the transduction efficiency in mammalian cells can be maintained.

This invention belongs to the field of regenerative medicine technology, specifically relating to bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1, their preparation method, and applications. The steps are as follows: Primary mouse bone marrow mononuclear precursor cells are cultured in expansion medium for 7 days to obtain macrophages, with the medium changed every 2-3 days during this period; on the 7th day, the expansion medium is replaced with a high-efficiency induction medium and cultured for 46-50 hours to obtain bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1. This invention, through a time-series strategy of TGF-β pre-induction combined with IL-4 / IL-5 / IL-13 synergistic induction, can significantly enhance the expression levels of CD301b, TIMD4, and LYVE-1 in BMDM, making their function close to that of natural cardiac resident macrophages, and effectively exerting anti-inflammatory, repair-promoting, and ventricular remodeling-inhibiting effects after AMI.

The present invention relates to the technical field of recombinant protein design and synthesis, and specifically discloses a recombinant spider silk protein and its synthesis method. The recombinant spider silk protein provided by the present invention undergoes optimized design such as replacement of the N-terminal and C-terminal domains of different spider species and different spider silk types, and large fragment recombination of the middle functional domain repeat sequences. A series of recombinant spider silk proteins are obtained through cell-free protein synthesis methods and prokaryotic fermentation expression. Compared with natural spider dragline silk proteins or other existing recombinant spider silk proteins, they generally have good composite mechanical properties and high-temperature resistance characteristics. At the same time, they have a relatively small molecular weight, significantly improving the total expression level and soluble expression, providing new raw materials and design and synthesis methods for the development of high-performance biomaterials.

A method for collecting blood and preparing serum from giant freshwater prawns includes: feeding the prawns a nutrient-rich diet under low-temperature conditions, collecting blood from their second walking legs, and obtaining purified serum through blood coagulation, serum precipitation, and further processing; the nutrient diet includes at least a protocatechuic acid-chitosan oligosaccharide derivative, which is obtained by grafting protocatechuic acid onto chitosan oligosaccharide. This invention preserves the life of individual giant freshwater prawns during blood collection and increases the amount of blood and serum collected.